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Abstract
The non-mevalonate dependent (NMVA) pathway for the biosynthesis of isopentenyl 
pyrophosphate and dimethylallyl pyrophosphate is the sole source of these terpenoids for the 
production of isoprenoids in the apicomplexan parasites, in many eubacteria, and in plants. The 
absence of this pathway in higher organisms has opened a new platform for the development of 
novel antibiotics and anti-malarials. The enzyme catalyzing the first step of the NMVA pathway is 
1-deoxy-D-xylulose-5-phosphate synthase (DXPS). DXPS catalyzes the thiamine pyrophosphate- 
and Mg (II)-dependent conjugation of pyruvate and D-glyceraldehyde-3-phosphate to form 1-
deoxy-D-xylulose-5-phosphate and CO2. The kinetic mechanism of DXPS from Deinococcus 
radiodurans most consistent with our data is random sequential as shown using a combination of 
kinetic analysis and product and dead-end inhibition studies. The role of active site amino acids, 
identified by sequence alignment to other DXPS proteins, was probed by constructing and 
analyzing the catalytic efficacy of a set of targeted site-directed mutants.
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Introduction
Isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) are the 
precursors for isoprenoids, the largest family of biologically active compounds. The 
isoprenoid family of molecules represents the most diverse set of biochemical entities known 
and are of considerable biological importance. For example, cholesterol (an isoprenoid) 
Under License of Creative Commons Attribution 3.0 License
*Corresponding author: David J. Merkler, merkler@usf.edu, Department of Chemistry, University of South Florida, USA., Tel: 
813-974-3579, Fax: 813-974-3203. 
HHS Public Access
Author manuscript
Biochem Mol Biol J. Author manuscript; available in PMC 2018 March 14.
Published in final edited form as:
Biochem Mol Biol J. 2018 ; 4(1): . doi:10.21767/2471-8084.100051.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
serves as a precursor to the glucocorticoids, the androgens, the mineralocorticoids, the 
gestagens, and estrogen [1,2]. The biomedical importance of the isoprenoids has intrigued 
the scientific community on numerous levels for decades, with one of the earliest questions 
being: “How these molecules are synthesized in the cell?” This question was answered for 
cholesterol by Bloch, Cornforth, Lynen, and Popják in the 1930’s through the 1960’s [3–6]. 
The pathway defined by these researchers from acetyl-CoA to cholesterol is outlined in 
almost every undergraduate biochemistry textbook. A key intermediate in the canonical 
pathway of cholesterol and the isoprenoid biosynthesis is mevalonate.
For many years, it was thought that IPP, DMAPP, and all the biologically-occuring 
isoprenoids were derived solely from the mevalonate-dependent (MVA) pathway. An 
alternative pathway to IPP, DMAPP, and the isoprenoids was discovered by 1990’s, which 
accounts for isoprenoid production in the apicomplexan parasites, many eubacteria, green 
algae, and plants [7]. In this alternative pathway, IPP is not derived from mevalonate, but 
from pyruvate and glyceraldehyde-3-phosphate. A 5-carbon sugar phosphate, xylulose-5-
phosphate is a key intermediate in the mevalonate-independent pathway of isoprenoid 
biosynthesis [7–9]. The enzymes catalyzing the reactions of the non-mevalonate dependent 
pathway (NMVA, also called the mevalonate-independent pathway or MEP) are completely 
different than the enzymes of the mevalonate dependent pathway (MVA). Many human 
pathogens produce their isoprenoids exclusively via NMVA or a combination of the MVA 
and NMVA, including Plasmodium spp, Mycobacterium tuberculosis, Chlamydophila 
pneumoniae, Treponema pallidum.
The first committed step in the NMVA involves the thiamine pyrophosphate- and divalent 
metal ion-dependent condensation of pyruvate (Pyr) and D-glyceraldehyde-3-phosphate 
(GAP) to form 1-deoxy-D-xylulose-5-phosphate (DXP) and CO2; as catalyzed by 1-deoxy-
D-ylulose-5-phosphate synthase (DXPS) (Figure 1) [10]. DXP, the product of the DXPS 
reaction, is used not only for the production of IPP, DMAPP, and the isoprenoids, but also 
for the biosynthesis of thiamin (vitamin B1) and pyridoxal (vitamin B6) in Plasmodium and 
other organisms [11–13]. Up- and down-regulation of DXPS expression in Arabidopsis 
thaliana results in the commensurate changes in the level of the isoprenoid levels providing 
strong evidence that DXPS catalyzes the rate-determing step of NMVA in this organism [14] 
and, by extension, in others.
The focus of the present study is to define the active site pocket of DXPS from Deinococcus 
radiodurans by constructing a set of site-directed mutants and to elucidate the order of 
substrate binding using steady-state kinetic analysis, product inhibition with DXP, and a 
dead end inhibition with β-fluoropyruvate. This work fosters a better understanding of the 
DXPS-catalyzed reaction and will aid in the rational design of DXPS inhibitors for the 
treatment of malaria and other human diseases.
Materials and Methods
Materials
Thiamine pyrophosphate (TPP), pyruvate, D,L-glyceraldehyde-3-phosphate (GAP), 1-
deoxy-D-xylulose-5-phosphate sodium salt, bovine serum albumin, and LB-broth were 
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purchased from Sigma Aldrich. NADPH was purchased from Alexis Biochemical, Ni-NTA 
resin was purchased from Invitrogen, and β-mercaptoethanol (β-Me) was purchased from 
Fisher. E. coli XL-10 cells, deoxynucleotide mix PCR grade, pfuUltra Hotstart DNA 
polymerase, QuikChange II site directed mutagenesis kit and acetonitrile (HPLC grade) 
were purchased from Agilent. The DNA vectors, pET28a (+) and pET15b (+), and E. coli 
BL-21 B (DE3) cells were purchased from EMD Biosciences. DNA sequencing services and 
primers were purchased from MWG operon. All the other reagents were of the highest 
quality commercially available.
Cloning of D. radiodurans DXPS and E. coli 1-Deoxy-D-xylulose 5-phosphate 
Reductoisomerase (DXR)
A synthetic, codon optimized D. radiodurans dxps gene with 5′-NdeI and 3′-XhoI 
restriction sites in a pMK vector was purchased from Geneart (Germany). The dxps gene 
was excised from the pMK vector and cloned into the NdeI and XhoI sites of a pET28a (+) 
vector (kanamycin resistance) with N-terminal His6-tag to yield the pET28a (+)-pxps 
plasmid. Successful cloning of the D. radiodurans dxps gene was confirmed by DNA 
sequencing at MWG Operon.
A synthetic, codon optimized E. coli dxr gene with 5′-NdeI and 3′-BamHI restriction sites 
in a pMK vector was purchased from Geneart (Germany). The dxr gene was excised from 
pMK vector and cloned into NdeI and BamHI restriction sites of pET15b (+) vector with a 
C-terminal His6 tag to yield the pET15b (+)-dxr plasmid. Gene insertion was confirmed by 
DNA sequencing.
Production of the D. radiodurans DXPS mutants
Site-directed mutagenesis was carried out using the QuikChange II site-directed mutagenesis 
kit. Briefly, the mutagenesis mixture consists of 50–100 ng plasmid pET28a (+)-dxps as a 
template, 1X PCR reaction buffer, 0.4 mM each of the forward and reverse primer, 0.25 mM 
dNTP mixture, 5 μL Quik solution, and 2.5 units of pfu Ultra hot-start polymerase in a 50 
μL reaction. The overlap extension method was used to produce the DXPS mutant that was 
difficult to create via site directed mutagenesis [15]. The sequence of the mutant DNA was 
confirmed by DNA sequencing.
Over-expression and purification of Wildtype DXPS and the DXPS mutants
Plasmids containing the wild type D. radiodurans dxps gene or the mutant dxps gene were 
transformed into E. coli BL-21 B (DE3) cells and used for protein expression. An overnight 
culture of E. coli in LB broth containing 50 μg/mL kanamycin was diluted 100-fold, 
cultured at 37°C until the absorbance at 600 nm reached ~0.6, and then cooled to 20°C. 
Expression was induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG). The cells were harvested by centrifugation (6,000 × g for 10 min) after being shaken 
for 6 hrs at 20°C and the resulting cell pellets stored at −80°C before purification. Cells were 
thawed and all the purification steps were performed at 4°C. Cells were resuspended in 
binding buffer (20 mM Tris, 500 mM NaCl, 5 mM imidazole, 10 mM β-mercaptoethanol (β-
Me), pH=7.5) supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF), 4 μg/mL 
leupeptin, and 2 μg/mL pepstatin, sonicated using a Heat systems W-380 ultrasonic 
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processor, and centrifuged (16,000 × g for 20 min) to remove cell debris. The supernatant 
from the cell lysate was applied to a 1.5 cm × 5 cm column packed with Ni-NTA resin that 
had been equilibrated with binding buffer. Non-bound proteins eluted from the column by 
first washing with 5 column volumes of binding buffer followed by 20 column volumes of 
wash buffer (20 mM Tris pH 7.5, 500 mM NaCl, 60 mM imidazole, and 10 mM β-Me). The 
bound DXPS (wildtype or mutant) was eluted from the Ni-NTA resin using elution buffer 
(20 mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole, and 10 mM β-Me). A flow rate of 
1.5 mL/min was maintained through the Ni-NTA column for all the loading and washing 
steps. DXPS-containing fractions containing were combined, exhaustively dialyzed at 4°C 
against 20 mM Tris pH 7.5, 100 mM NaCl, and 10 mM β-Me, and concentrated by 
ultrafiltration. The final yield of DXPS (wildtype or mutant) was 7–8 mg/L of E. coli culture 
medium. Enzyme was flash frozen in liquid nitrogen, stored at −80°C. The purity of the 
DXPS (wildtype or the mutant) was evaluated by SDS-PAGE.
Determination of GAP and DXP concentration
D,L-GAP was obtained from Sigma Aldrich as a suspension in water. The concentration of 
D-GAP was measured spectrophotometrically using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). A reaction mixture (0.5 mL) containing 30 mM sodium 
pyrophosphate buffer pH 8.6, 5 mM L-cysteine, 0.6 mM NAD+, 0.6 mM sodium arsenate, 
and D, L-GLP at concentration less than 0.2 mM were incubated at 30°C for 10 min, the 
reaction initiated with 2 μg of GAPDH (Novus Biotechnology), and the progress of the 
reaction monitored spectrophotometrically at 340 nm. The final concentration of D-GAP 
was calculated based on the production of NADPH (ε340=6,220 M−1 cm−1). Throughout this 
work, the abbreviation “GAP” represents the concentration of D-glyceraldehyde-3-
phosphate in the racemic mix.
DXP was purchased from Sigma Aldrich as the sodium salt. The salt was resuspended in 10 
mM HEPES buffer (pH=6.0), and the concentration was measured spectrophotometerically 
using DXR. A reaction mixture (0.5 mL) containing of 100 mM HEPES pH 8.0, 1 mg/ml 
BSA, 1.5 mM MnCl2, 0.3 mM NADPH, and DXP at concentration less than 0.1 mM were 
incubated at 37°C for 5 min, the reaction initiated with 1.25 μg of DXR, and the progress of 
the reaction monitored spectrophotometrically at 340 nm. Final concentration of DXP was 
calculated based on the oxidation of NADPH (ε340=6,220 M−1 cm−1).
Assays for DXPS activity
One assay we employed to measure DXPS activity involved a DXPS-DXR coupled assay. In 
this way, the DXPS-dependent production of DXP is ultimately coupled to the oxidation of 
NADPH to NADP+. The solution for the DXPS-DXR coupled contained 100 mM HEPES 
pH 8.0, 100 mM NaCl, 1 mg/ml BSA, 1 mM TPP, 1.5 mM MnCl2, 2 mM β-Me, 0.15 mM 
NADPH, 0.2 mg/ml DXR, and varying concentrations of pyruvate or GAP [16]. Steady-state 
kinetic experiments were performed by varying pyruvate or GAP at a fixed saturating 
concentration of the co-substrate. A DXPS-DXR reaction solution was incubated at 37°C for 
5 min, the reaction was initiated by addition of 358 nM DXPS, and the progress of the 
reaction monitored spectrophotometrically at 340 nm for the oxidation of NADPH.
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Another assay we employed to measure DXPS activity was an HPLC determination of net 
[DXP] production or [GAP] consumption, modified from a published procedure [17]. This 
endpoint assay to measure DXPS activity was used in our product inhibition studies. Briefly, 
the reaction was initiated by addition of 573 nM DXPS. At the desired time, an aliquot (50 
μL) was removed and added to an equal volume of acidic 2,4-dinitrophenol (DNP) (100 mM 
2,4-DNP in 2N H2SO4) to terminate the enzymatic reaction. After a 5 minute incubation at 
room temperature, the pH was adjusted to 5–7 by addition of 36 μL 4.0 M Tris buffer pH 
10.0 and centrifuged to remove excess 2,4-DNP. The DNP derivatives of pyruvate, GAP, and 
DXP were separated using a 5 μm Discovery® C18 column (25 cm × 4.6 mm) developed 
using the following conditions: flow rate=1.5 mL/min; solvent A, 100 mM ammonium 
acetate pH 4.6, 0.05% TFA; solvent B, acetonitrile, 0.05% TFA; 20% – 35% solvent B over 
12 min; and then 35–60% solvent B over 2 min. When varying [pyruvate] at one fixed 
[GAP], the concentrations used for the initial velocity kinetic experiments were as follows: 
1.0 mM GAP and pyruvate at 0.26, 0.50, 0.75, or 4.0 mM; and DXP at 0, 0.2, 0.3, or 0.4 
mM. The DXP hydrazone peak area was measured and the DXP concentration was 
determined against a standard curve generated using DXP hydrazone. When carrying the 
DXP inhibition studies, net [DXP] produced was determined by substrating background 
[DXP] at zero time (before the addition of enzyme) from the total [DXP] produced at the 
desired time interval. When varying [GAP] at one fixed [pyruvate], the concentrations used 
for the initial velocity kinetic experiments were as follows: 0.3 mM pyruvate and GAP at 
0.05, 0.1, 0.25, and 0.50 mM; and DXP at 0, 0.2, 0.3, or 0.4 mM. The GAP hydrazone peak 
area was measured and the GAP concentration was determined compared against a standard 
curve generated using GAP hydrazone. Assays were performed in duplicate.
Inhibition of DXPS by β-fluoropyruvate (F-Pyr)
Initial reaction velocities were determined using the DXPS-DXR coupled assay. When 
varying [pyruvate] at one fixed [GAP], the concentrations used for the initial velocity kinetic 
experiments were as follows: 0.5 mM GAP, pyruvate, 0.1 mM, 0.18 mM, 0.5 mM, or 2 mM; 
and F-Pyr at 0 μM, 25 μM, 50 μM, 75 μM or 100 μM. When varying [GAP] at one fixed 
[pyruvate], the concentrations used for the initial velocity kinetic experiments were as 
follows: 2.0 mM pyruvate and GAP at 0.025 mM, 0.05 mM, 0.125 mM, or 0.25 mM; and F-
Pyr at 0, 25 mM, 50 mM, 75 mM or 100 μM. Assays were performed in triplicate using 115 
nM of D. radiodurans DXPS and the data were fit using nonlinear least-squares regression 
analysis.
Analysis of the initial velocity kinetic data
The steady state initial velocity for DXPS measured at various concentrations of pyruvate 
and GAP were fit to equation 1 using nonlinear regression analysis in Sigma-Plot 12.0 Data 
for inhibition of DXP and fluoropyruvate against pyruvate and GAP were fit to equation 2, 3 
and 4 for competitive, noncompetitive, and uncompetitive, respectively, where [I] is the 
concentration of inhibitor and Ki is the inhibition constant with respect to β-fluoropyruvate.
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Results and Discussion
Overexpression and purification of D. radiodurans DXPS
A synthetic, codon-optimized wildtype D. radiodurans dxps gene (dxps-wt) with a N-
terminal His6 tag was cloned into the pET28a (+) vector using NdeI and XhoI restriction 
sites. A series of D. radiodurans DXPS mutant proteins were constructed near the active site 
pocket using the dxps-wt gene as template by the Quikchange site-directed mutagenesis 
method or the overlap extension method [15]. Wildtye enzyme (DXPS-WT) and the mutant 
enzymes (all possessing N-terminal His6 tag) were affinity purified using the Ni-NTA resin 
to >95% pure with respectable expression yields of 6–8 mg per liter of culture.
Comparison of steady-state kinetic parameters between mutant DXPS proteins and 
wildtype enzyme
We have constructed and evaluated a set of mutant D. radiodurans DXPS proteins. DXPS is 
a TPP- and Mg (II)-dependent enzyme that belongs to the transketolase (TK) family of TPP-
dependent enzymes [18,19]. The sequences of E. coli and D. radiodurans DXPS are 45% 
identical and their respective structures are remarkably similar. The rms distance of 
equivalent Cα atoms between the two structures is only 0.7Å [19]. Despite low sequence 
identity to other TK family members, E. coli and D. radiodurans structures are similar to that 
of yeast transketolase (TK), the E1 subunit of E. coli pyruvate dehydrogenase (PDH), and P. 
putida 2-oxoisovalerate dehydrogenase [19,20]. DXPS is a dimer, with each monomer 
possessing three domains: domains I, II, and II (Figure 2). Domain I is composed of residues 
1–319, domain II is composed of residues 320–495, and domain III is composed of residues 
496–629. The DXPS active site is found at interface of domains I and II within the same 
monomer (Figures 3 and 4) [19,20]. In constrast to DXPS, the active site of other TPP-
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dependent enzymes is located at the interface of domain I of one monomer and domain II of 
the second monomer, examples include the E1 component of E. coli pyruvate dehydrogenase 
[21], yeast transketolase [22], yeast acetohydroxyacid synthase [23], Bifidobacterium 
longum phosphoketolase [24]. TPP is bound deeply within a cleft formed from segments of 
domain I and II and adopts a V-conformation, like that found in other TPP-dependent 
enzymes [19]. The V-conformation of TPP positions the 4′-imino group to deprotonate the 
C2 atom, thus, forming the catalytically important C2 carbanion [25,26]. Sequence 
alignments of DXPS proteins from a number of different organisms show extensive 
sequence identity at the binding sites for TPP and GAP [19,20].
Domain I mutants
A structural feature common too many TPP-dependent enzymes is the presence of three 
discrete domains, as was found for DXPS. The Pyr domain interacts with the pyrimidine 
ring of the TPP cofactor and PP domain interacts with the pyrophophosphate tail of TPP. 
The function of the third domain is unclear, but may serve a regulatory function as this 
domain is structurally related to nucleotide binding domains in other proteins [27]. As 
reviewed by Duggleby [27], the relative arrangement of the three domains is different within 
the various families of the TPP-dependent enzymes. Domain I of D. radiodurans DXPS is 
the PP domain and functions primarily in the binding of the pyrophosphate moiety of TPP. 
The DXPS-bound Mg (II) is coordinated to the TPP pyrophosphate, meaning the amino 
acids necessary for Mg (II) binding are found within domain I. GAP is bound within a 
pocket that is composed of amino acids from both domains I and II; thus, domain I also has 
a role in GAP binding.
The results for the domain I mutants constructed herein are shown in Tables 1 and 2. His-82 
and His-304 are two amino acid residues involved in TPP binding: the N3 imidazole His-82 
is 5.6Å from C2 of the thiazolium ring and the N1 of the imidazole of His-304 is 5.2Å from 
the C2 of the thiazolium ring. Also, the N1 of the imidazole is 4.1Å from N1 of the 
imidazole of His-304 in D. radiodurans DXPS. The mutation of both to Ala, generating 
separate H82A and H304A mutant proteins, yielded catalytically defective enzymes with 
Vmax and (V/K)app values of 2–12% of wild-type. Given the proximity of His-82 and 
His-304 in the D. radiodurans DXPS structure, it seems likely that these amino acids could 
function “in reserve” of each other accounting for the ~10% remaining in both H82A and 
H304A mutants. In other words, His-304 can partially fulfill the role played by His-82 in 
catalysis after its mutation to Ala.
The KM,app values for the H82A mutant for both GAP and pyruvate are similar to wildtype 
indicating that His-82 contributes little to the binding of either substrate. Similar to our 
results for the H82A mutant, mutation of the equivalent amino acid in yeast transketolase, 
His-69, to Ala yielded an enzyme with a VMAX that is 1.5% of wildtype and virtually the 
same KM for the acceptor substrate (ribose 5-phosphate for transketolase and GAP for 
DXPS). In contrast to our results for H82A, the donor substrate KM in yeast transketolase 
does increase 6-fold [28]. These data indicate that His-82 and His-69 serve to stabilize the 
α-carbanion/enamine-TPP intermediate produced from the donor substrate in DXPS and 
transketolase, which was observed later in the structure of the yeast transketolase-α, β-
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dihydroxyethyl-TPP complex [29]. One difference between the two enzymes is the role 
served by His-82 or His-69 in donor substrate binding. In D. radiodurans DXPS, His-82 
seems to have no role in donor substrate binding while in yeast transketolase, His-69 does 
contribute to donor substrate binding.
The results for the H304A mutant differed from that of H82A as the KM,app for GAP was 
similar to wildtype, but the KM,app value for pyruvate was 6-fold higher than wildtype. The 
structure of D. radiodurans DXPS shows that His-304 is located within an open cavity near 
the thiazolium C2 atom and, thus, likely contributes to both pyruvate binding and 
stabilization of the α-carbanion/enamine-TPP intermediate.
Other mutations that were constructed within domain I were N181A and N183A. Asn-183 is 
coordinated to the bound Mg (II) ion and mutation of this residue to Ala results in a 
completely inactive protein. In contrast to N183A, the N181A mutant retains activity 
exhibiting 10% of (V/K)app,GAP and 70% of (V/K)app,pyruvate. The KM,app values for both 
substrates are approximately the same as wildtype for the N181A mutant; thus, the decrease 
in (V/K)app reflects a decrease in catalytic efficiency upon mutant of Asn181 to Ala. The 
amino acid equivalent to Asn-181 in yeast transketolase is Asp-185. The structure of yeast 
transketolase showns that Asp-185 is involved in a network of bound water molecules 
important in Ca (II) chelation and pyrophosphate binding in this enzyme. Asn-181 may 
serve a similar role in D. radiodurans DXPS. A mutation in this residue could subtly alter 
the active site architecture such that the TPP is no longer optimally positioned for catalysis. 
Models of the domain I mutants illustrating the critical active site amino acids and hydrogen 
bonds are shown in Figure 3.
Domain II mutants
Amino acids 320–495 of D. radiodurans DXPS define domain II, which primarily interacts 
with the thiazolium and aminopyrmidine rings of TPP. Thus, domain II in DXPS is the Pyr 
domain [27]. Domain II also serves an important role in the binding of both substrates, GAP 
and pyruvate [19,20]. Of the amino acids in domain II that we altered via mutagenesis, the 
largest effects on catalysis were observed in changing Arg-423 (Tables 3 and 4). Arg-423 is 
conserved in other DXPS enzymes and has a role in GAP binding resulting from the 
formation of hydrogen bond between its guanidino group and the phosphate of GAP. 
Mutation of Arg-423 to a lysine yields an enzyme with considerable residual activity (50–
80%), but with altered KM values; the KM,GAP increasing 12-fold and the KM,pyruvate 
decreasing 5-fold. Mutation of Arg-423 to an alanine yields a mutant enzyme with little 
activity, a (V/K) app that is 0.1% of wildtype. The KM,GAP for the R423A mutant is 
approximately equivalent to the KM for glyceraldehyde in DXPS WT (14 mM), providing 
additional evidence that the guanidino moiety of Arg-423 interacts with the phosphate of 
GAP. The amino acid equivalent to Arg-423 in D. radiodurans DXPS in yeast transketolase 
is His-469. The structure of yeast transketolase shows that imidazole of His-469 forms a 
hydrogen bond with the phosphate of the acceptor substrate (erythrose 4-phosphate) [30] 
and, in addition, may form a similar hydrogen bond to the phosphate in the substrate-TPP 
adduct [31]. In contrast to the R423 mutant described herein, the yeast transketolase H469A 
mutant retains considerable activity, but exhibits ~10-fold higher KM values for both 
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substrates. While Arg-423 and His-469 have key roles in the binding of the phosphorylated 
substrates in both DXPS and transketolase, the positive charge of Arg-423 is more important 
to catalysis in DXPS than that of His-469 in transketolase.
Modeling studies suggest that the hydroxyl group of Tyr-395 interacts directly with the 
phosphate of GAP, yet it has been reported that the mutation of the equivalent tyrosine 
residue in E. coli DXPS, Tyr-392, has little effect on catalysis [19]. Both the Y392A and 
Y392F mutants of E. coli DXPS are more active than wildtype enzyme. We find that 
mutation of Tyr-395 in D. radiodurans DXPS does compromise catalytic efficiency as both 
the Y395A and Y395F mutant exhibit kcat/KM values that are only >10% of that of wildtype 
(Table 1) ;or GAP. The decrease in catalytic efficiency in both the Y395A and Y395F 
mutants is largely reflected in a >10-fold increase KM for both proteins. The Y395F mutant 
is a better catalyst than the Y395A mutant: (kcat/ KM)Y395F/(kcat/KM)Y395A=1.7, indicating 
that the aromatic ring and hydroxyl group of Y395 contribute positively to catalysis. This is 
consistent with studies of the amino acid equivalent of Tyr-395 in yeast transketolase, 
Phe-442, showing that aromatic side chain of Phe-442 contributes to a hydrophobic binding 
pocket for the pyridine ring of the TPP cofactor [31].
Like Tyr-395, Asp-430 is thought to interact with GAP, in this case, forming a hydrogen 
bond to the hydroxyl group at carbon-2. The equivalent amino acid in yeast transketolase, 
Asp-477, similarly forms a hydrogen bond to the 2-hydroxyl group of erythrose 4-phosphate 
[30]. Mutagenesis of Asp-430 to alanine yields a mutant enzyme that retains considerable 
activity, with a V/K that is ~50% of wildtype, resulting from a ~2-fold increase in the KM 
for both substrates (Table 1). Construction of the similar mutant in yeast transketolase, 
D477A, yielded a protein of much lower activity, 1–2% of wildtype, with relatively greater 
values for the substrates. The KM for the donor substrate in the D477A mutant, xylulose 5-
phosphate, increased 9-fold while that for the acceptor substrate, ribose 5-phosphate, 
increased 12-fold [30]. In the reaction catalyzed by DXPS, pyruvate is the donor substrate 
and GAP is the acceptor substrate. These data suggest that Asp-477 in yeast transketolase 
has a more important role in acceptor substrate binding and catalysis that Asp-430 in D. 
radiodurans DXPS.
The amino acid equivalent of His-434 in D. radiodurans DXPS is His-481 in yeast 
transketolase and Gln-428 in human transketolase [32]. Mutation of Gln-428 to Ala, His, 
Asn, or Glu in human transketolase yields an enzyme that retains activity with the Vmax 
values ranging from 5% of wildtype for Q428E to 18% of wildtype for Q428N. More 
detailed analysis Q428 shows no difference in the KM values relative to wildtype for either 
the donor or acceptor substrates, but with a decrease in VMAX to 15% of wildtype. These 
results suggested that Gln-428 was not important to substrate binding in human 
transketolase, but was important to catalysis. Singleton et al. suggested that Gln- 428 aids in 
orienting an active site water molecule critical to the optimum positioning of TPP [32]. 
Mutagenesis studies of His-481 in yeast transketolase differed from what was found for 
Gln-428 in the human enzyme. Conversion of His-481 to Ala, Ser, or Gln produced of lower 
activity, with the Vmax values all ≤ 5% of wildtype. Steady-state kinetic analysis of the yeast 
transketolase mutants showed no effect on the KM for the acceptor substrate, but a large 
increases in the KM value for the donor substrate, ranging from an 18-fold increase for 
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H481A to 58-fold for the H481Q [28]. Crystallographic studies of yeast transketolase in the 
presence of β-hydroxypyruvate only, which will form the enzyme bound α,β-
dihydroxyethyl-thiamin intermediate, shows that His- 481 interacts with the donor substrate 
and forms a stabilizing hydrogen bond from the N1 of the imidazole ring to the C2 hydroxyl 
of this intermediate [29].
Analysis of the H434A mutant of D. radiodurans DXPS yielded results that differed from 
what has been reported for human and yeast transketolases. The Vmax of the H434 mutant is 
higher than that of wildtype, Vmax (H434)/Vmax (wildtype)=1.2 – 1.3, and the KM values for 
both the donor and substrates in the H434 mutant are also increased approximately the same 
relative to wildtype. Mutagenesis of the equivalent amino acid in E. coli DXPS, His-431, to 
alanine produced an enzyme with the same activity as wildtype [19], consistent with our 
data on the D. radiodurans enzyme. The KM for GAP increased 4-fold while the KM for 
pyruvate increased 6-fold (Table 3). Modeling studies of D. radiodurans DXPS suggest that 
His-434 is located with the GAP binding pocket without an obvious direct interaction with 
the substrate. The negatively charged phosphate of GAP seems to dock into a positively 
charged well in the active site and His-434 seems to contribute to this positively charged 
active site well. Based on the model of pyruvate-TPP adduct in D. radiodurans DXPS, it is 
conceivable that pyruvate may also interact with this postively charged well in the active 
site. Replacement of His-434 with alanine will decrease the net positive charge of the well 
and increasing the KM for both substrates with little effect on the rate of catalysis. Models of 
the domain II mutants illustrating the critical active site amino acids and hydrogen bonds are 
shown in Figure 4.
Inhibition and kinetic studies
The kinetic mechanism has been investigated for many TPP-dependent enzymes; a classic 
ping-pong scheme is common within this family of enzymes [33–35]. A ping-pong kinetic 
mechanism means that first substrate binds followed by the release of the first product 
before the second substrate binds. DXPS is an unusual TPP-dependent enzyme as substrates, 
pyruvate and GAP, bind before pyruvate is decarboxylated; thus, the kinetic mechanism for 
DXPS is not ping-pong [36–39]. Consistent with this unusual aspect of DXPS-mediated 
catalysis is the incredible stability of the C2-α-lactyl-TPP intermediate within the active site 
[38]. The binding of GAP to form the E•C2-α-lactyl- TPP•GAP ternary complex triggers 
CO2 release, yielding the C2- α-carbanion/enamine that will react with GAP to produce 
DXP [38,39]
Dead-end inhibition studies and 14CO2 trapping experiments demonstrated that the 
Rhodobacter encapsulates DXPS has an ordered sequential mechanism with pyruvate 
binding first [36]. Eubanks and Pouter [36] found that the conversion of pyruvate to 14CO2 is 
inefficient in absence of GAP, consistent with stability of the DXPS-bound C2-α-lactyl-TPP 
intermediate. Studies of E. coli DXPS showed that the kinetic mechanism for this enzyme 
was rapid equilibrium random; pyruvate and GAP binding to E. coli DXPS is reversible and 
completely independent of each other [37–39].
In our study of D. radiodurans DXPS, we employed a set of steady-state kinetic experiments 
by varying the concentration of one substrate and at constant, but different concentrations of 
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the other substrate. Results from these experiments were coupled with product (DXP) 
inhibition data and dead-end inhibition data (β-fluoropyruvate) to provide information 
regarding the kinetic mechanism. Double reciprocal analysis at lower concentrations of 
pyruvate (0.02 mM - 0.06 mM) (Figure 5A) and GAP (0.01 – 0.03 mM) (Figure 5B) at 
different, but fixed concentrations of the other substrate revealed a non-competitive pattern 
with change in both slope and intercept, eliminating a ping-pong and rapid equilibrium 
ordered kinetic mechanism [40]. The lack of curvature in the plots at high substrate 
concentration further suggests that the kinetic mechanism for D. radiodurans DXPS is not 
steady-state random [40,41].
Product inhibition studies were next used to determine the mechanism of substrate binding 
and product release in the D. radiodurans DXPS catalyzed reaction. DXP was used as 
product inhibitor against pyruvate and GAP. We found that DXP is a weak inhibitor with 
~60% inhibition at concentration of 0.4 mM, yielding a Ki in low millimolar range (Table 5). 
DXP showed a competitive pattern vs. pyruvate indicating that DXP competes for the same 
enzyme form as pyruvate (Figure 6A), despite the chemical resemblance between DXP and 
GAP. When GAP was the varied substrate at fixed sub-saturating concentration of pyruvate, 
DXP yielded a non-competitive inhibition pattern (Figure 6B). This shows that DXP and 
GAP do not bind to the same enzyme form. At a saturating concentration of pyruvate, no 
inhibition was detected by DXP when GAP was varied substrate. On the other hand, DXP 
inhibition was still observed at saturating concentration of GAP when pyruvate was the 
variable substrate. F-Pyr was used as a dead-end inhibitor to further study the order of 
substrate binding in D. radiodurans DXPS. F-Pyr is competitive vs. pyruvate (Figure 7A) 
and non-competitive vs. GAP (Figure 7B) and exhibits a Ki=3.3 μM when pyruvate was the 
variable substrate. In sum, all the data presented herein, (a) the DXP inhibition patterns, (b) 
the double reciprocal plots obtained in varying both substrates, and (c) the F-Pyr inhibition 
point to either a Theorell-Chance ordered, steady-state ordered, or rapid equilibrium random 
kinetic mechanism. A Theorell- Chance kinetic mechanism, a scheme that requires the lack 
of a kinetically significant E•C2-α-lactyl-TPP•GAP ternary complex, seems unlikely given 
the results of Brammer-Basta et al. [39] for E. coli DXPS and is not commonly found as a 
kinetic mechanism for TPP-dependent enzymes. Mostly likely kinetic mechanism for D. 
radiodurans DXPS is rapid equilibrium random. Note that a random mechanism could 
evolve to an ordered mechanism at high [pyruvate], similar to that reported for R. capsulatus 
DXPS [36]. At high [pyruvate], the D. radiodurans DXPS-catalyzed conversion of pyruvate 
and GAP to DXP and CO2 would proceed preferentially through path A relative to path B 
(Figure 8).
Conclusion
We have produced and characterized a series of D. radiodurans DXPS mutants, the selection 
based upon the sequence alignment of a number of DXPS enzymes and relationships to key 
amino acids in other TPP-dependent enzymes. Mutant proteins were constructed of these 
domain I amino acids, His-82, Asn-181, Asn-183, and His-304, and these of domain II, 
Tyr-395, Arg-423, Asp-430, and His-434. The results of our mutation studies point to 
differences in the roles for Arg-423, Asp-430, and His-434 in substrate binding and catalysis 
for D. radiodurans DXPS relative to the equivalent amino acids in transketolase, another 
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TPP-dependent enzyme. Since Arg-423, Asp-430, and His-434 are all found within domain 
II in D. radiodurans DXPS our data point towards broad differences in the role of domain II 
in substrate binding and catalysis in DXPS relative to transketolase. Another outcome from 
our mutagenesis work on D. radiodurans DXPS is identification of a potential “back-up” 
role between His-82 and His-304 in catalysis meaning that one of these His residues can 
fulfill the catalytic role of the other when the other His is converted to Ala by mutagenesis. 
We complemented our mutagenesis studies with experiements demonstrating that the kinetic 
mechanism of D. radiodurans DXPS is, most likely, rapid equilibrium random similar to that 
reported for E. coli DXPS. DXPS catalyzes the first step in the non-mevalonate pathway of 
isoprenoid biosynthesis in many pathogens. DXPS and the other enzymes of this pathway 
represent drug targets as these enzymes have no homology the enzymes of the mevalonate-
dependent pathway of isoprenoid biosynthesis in man and other mammals. The work 
presented herein contributes to our understanding of TPP-dependent catalysis and provides 
information about the active site architechure and order of substrate binding for D. 
radiodurans DXPS. These data should aid in the rational design of DXPS inhibitors that to 
attack pathogens reliant on non-mevalonate pathway for their isoprenoids.
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Figure 1. 
The reaction catalyzed by DXPS (R1=4′-amino-2-methyl-5-pyrimdyl and R2=β-
hydroxyethyldiphosphate).
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Figure 2. 
Schematic of D. radiodurans DXPS depicting the bound TPP. This figure was created using 
Maestro 9.3.023 from Schrödinger suite 2012 and PDB 2o1x. Domain I of D. radiodurans 
DXPS is shown as purple ribbon, domain II of D. radiodurans DXPS is shown as green 
ribbon as ribbon, TPP is shown as tube with aquamarine carbon atoms, and the Mg (II) ion 
is shown as a pink sphere.
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Figure 3. 
Domain I of D. radiodurans DXPS including the bound TPP molecule. Domain I mutant 
enzymes (H82A, N181A, N183, and H304A) with the dashed lines representing hydrogen 
bonds and key residue highlighted in deep blue. The models in the column on the left show 
the wild-type enzyme while the mutant enzymes are shown in the models in the column on 
the right. These models do not represent all possible differences in hydrogen bonding due to 
the lack of substrates in the active but, no crystal structures of DXS currently exist 
containing the bound. The models were prepared utilizing PyMOL.
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Figure 4. 
Domain II of D. radiodurans DXPS including the bound TPP molecule. Domain II mutant 
enzymes (Y395A, Y395F, R423A, R423K, D430A, and the H434A) with the dashed lines 
representing hydrogen bonds and key residue highlighted in deep blue. The left column on 
the far left is a model for the wild-type enzyme while the models in the right column images 
illustrate the mutant enzymes. The top 2 rows are the three models that correlate with the 
Y395 and R423 mutants, respectively. The models were prepared utilizing PyMOL.
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Figure 5. 
Double reciprocal analysis of initial velocities of pyruvate and GAP at different fixed 
concentrations of the other substrate. Right panel: kinetic analysis was performed using sub-
saturating concentrations of GAP: 0.01 mM (●), 0.014 mM (○), 0.02 mM (▼), and 0.03 
mM (△). Left panel: kinetic analysis was performed using subsaturating concentration of 
pyruvate: 0.02 mM (●), 0.03 mM (○), 0.04 mM (▼), and 0.06 mM (△).
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Figure 6. 
Double reciprocal analyses of initial velocities of DXPS inhibition by DXP at different 
initial concentrations of pyruvate (right panel) and GAP (left panel). Kinetic analyses were 
performed using the following concentrations of DXP: 0 mM (●), 0.2 mM (○), 0.3 mM (▼) 
and 0.4 mM (▽).
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Figure 7. 
Double reciprocal analyses of initial velocities of DXPS inhibition by F-Pyr at different 
fixed concentration of pyruvate (right panel) and GAP (left panel). Kinetic analysis was 
performed using the following concentrations of F-Pyr: 0 μM (●), 25 μM (○), 50 μM (▼), 
75 μM (▽), and 100 μM (■).
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Figure 8. 
The random sequential pathway proposed for the reaction catalyzed by D. radiodurans 
DXPS. Pyr* is the C2-α-carbanion/enamine intermediate as shown in Figure 1.
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Table 1
Domain I mutants: Measurement of steady-state kinetic parameters with GAP is the variable substratea.
Protein KM,app (mM) kcat,app (s−1) (kcat/KM)app (s−1 M−1)
Wildtype 0.05 ± 0.01 7.9 ± 0.4 1.5 × 105 1.0
H82A 0.03 ± 0.01 0.37 ± 0.02 1.3 × 104 0.09
N181A 0.03 ± 0.01 0.43 ± 0.02 1.4 × 104 0.09
N183A 0 0 0 0
H304A 0.08 ± 0.02 0.90 ± 0.1 1.1 × 104 0.07
aApparent kinetic constants were measured by varying the initial concentration of GAP at an initial fixed concentration of 2.0 mM pyruvate.
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Table 2
Domain I mutants: Measurement of steady-state kinetic parameters with pyruvate is the variable substratea.
Protein KM,app (mM) kcat,app (s−1) (kcat/KM)app (s−1 M−1)
Wildtype 0.28 ± 0.03 7.4 ± 0.3 2.6 × 104 1.0
H82A 0.23 ± 0.02 0.38 ± 0.01 1.7 × 103 0.07
N181A 0.17 ± 0.02 3.3 ± 0.1 1.9 × 104 0.7
N183A 0 0 0 0
H304A 1.7 ± 0.5 0.90 ± 0.01 5.8 × 102 0.02
aApparent kinetic constants were measured by varying the initial concentration of pyruvate at an initial fixed concentration of 0.5 mM GAP.
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Table 3
Domain II mutants: Measurement of steady-state kinetic parameters with GAP is the variable substratea.
Protein KM,app (mM) kcat,app (s−1) (kcat/KM)app (s−1 M−1)
Wildtype 0.05 ± 0.01 7.9 ± 0.4 1.5 × 105 1.0
Y395A 0.67 ± 0.05 3.9 ± 0.1 5.8 × 103 0.04
Y395F 0.59 ± 0.04 5.9 ± 0.2 1.0 × 104 0.07
D430A 0.12 ± 0.01 7.7 ± 0.2 6.6 × 104 0.4
R423A 12 ± 3.2 1.7 ± 0.3 1.4 × 102 9 × 10−4
R423K 0.60 ± 0.1 6.4 ± 0.2 1.1 × 104 0.07
H434A 0.23 ± 0.01 9.6 ± 0.3 4.2 × 104 0.3
aApparent kinetic constants were measured by varying the initial concentration of GAP at an initial fixed concentration of 2.0 mM pyruvate.
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Table 4
Domain II mutants: Measurement of steady-state kinetic parameters with pyruvate is the variable substratea.
Protein KM,app (mM) kcat,app (s−1) (kcat/KM)app (s−1 M−1)
Wildtype 0.28 ± 0.03 7.4 ± 0.3 2.6 × 104 1.0
Y395A 0.16 ± 0.01 3.6 ± 0.1 2.2 × 104 0.8
Y395F 0.19 ± 0.01 2.9 ± 0.02 1.6 × 104 0.6
D430A 0.52 ± 0.03 7.2 ± 0.2 1.4 × 104 0.5
R423A NDb NDb NDb NDb
R423K 0.06 ± 0.01 3.9 ± 0.1 6.5 × 104 2.5
H434K 1.7 ± 0.1 9.9 ± 0.2 5.9 × 103 0.2+
aApparent kinetic constants were measured by varying the initial concentration of GAP at an initial fixed concentration of 0.5 mM GAP.
bND = Not Determined
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Table 5
Inhibition patterns and inhibition constants for the inhibition of D. radiodurans DXPS by DXP or β-
fluoropyruvate.
Inhibitor Substrate Pattern Ki (μM)
DXP Pyruvate Competitive 130 ± 32
DXP GAP Non-competitive 830 ± 160
F-Pyr Pyruvate Competitive 3.3 ± 0.4
F-Pyr GAP Non-competitive 57 ± 3.2
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